Strides Pharma Science has received a USFDA Establishment Inspection Report for its Bengaluru manufacturing facility, with the inspection outcome classified as Voluntary Action Indicated (VAI). The company announced the receipt of the report on August 19, 2026, confirming the successful closure of the inspection process for its flagship site.

Regulatory outcome

The USFDA conducted a current Good Manufacturing Practices (cGMP) inspection of the Bengaluru facility from May 12 to May 20, 2026. As previously disclosed on May 20, 2026, the initial inspection concluded with the issuance of a Form 483 containing five observations. Strides Pharma Science submitted a comprehensive response addressing all observations within the stipulated timeline.

Based on the company's response and the corrective and preventive actions implemented, the USFDA classified the final inspection outcome as VAI and issued the Establishment Inspection Report (EIR). A VAI classification denotes that while the agency may have noted minor observations, no mandatory corrective actions are required from the company, distinguishing it from the more stringent Official Action Indicated status.

The Bengaluru facility is Strides Pharma Science's flagship manufacturing site and serves regulated and other international markets. It manufactures a broad portfolio of pharmaceutical dosage forms, including tablets, capsules, and oral liquids, supporting both existing commercial products and future growth opportunities. Receipt of the EIR with a VAI classification confirms the formal closure of the USFDA inspection process for this site.

The successful closure of the inspection strengthens Strides Pharma Science's regulatory track record and reinforces its commitment to supplying high-quality pharmaceutical products to patients across global markets. The facility is part of the company's global manufacturing network, which includes sites in India, Italy, Kenya, and the United States.

Strides Pharma Science shareholders approved all six resolutions tabled at the company’s 35th annual general meeting (AGM) held on August 14, 2026. The meeting, conducted via video conferencing, covered routine corporate governance matters including the adoption of audited financial statements for FY26 and declaration of a final dividend.

The scrutinizer’s report confirmed that all resolutions passed with requisite majority through remote e-voting and polling at the meeting. A total of 97,939 shareholders were on record as of the cutoff date, with significant participation from both promoter and public shareholders.

Voting Participation Overview

Promoter group engagement remained consistently high across all resolutions, with e-voting participation ranging between 95% and 100% of shares held. Public institutional investors also showed strong engagement, particularly on financial and dividend-related resolutions.

Key Resolutions Approved

Shareholders approved the adoption of audited consolidated financial statements for the financial year ended March 31, 2026, along with reports from the Board of Directors and statutory auditors. The resolution received overwhelming support with 6,73,88,862 votes in favour against just 220 votes against.

The final dividend declaration for FY26 was also approved as an ordinary resolution. This resolution saw even higher support, with 6,76,53,890 votes cast in favour and only 165 votes against.

Board Appointments

Three director-related resolutions were placed before shareholders:

• Re-appointment of retiring director Arun Kumar as an ordinary resolution
• Appointment of Mr. Aditya Arun Kumar as non-executive director
• Appointment of Mr. Venkata Seetharama Raju Pakalapati as executive director (special resolution)

All three appointments received majority approval. The re-appointment of Arun Kumar saw 6,50,04,913 votes in favour, while institutional shareholders registered 13,78,932 votes against. Aditya Arun Kumar’s appointment received 6,68,87,882 favourable votes, with 7,07,748 votes cast against.

Special Resolution on Director Compensation

A special resolution seeking approval for payment of commission to non-executive directors in the event of profit inadequacy was also passed. This resolution garnered 6,68,83,210 votes in favour against 1,79,999 votes against.

Joseph & Chacko LLP served as scrutinizer for the remote e-voting process, which ran from August 10 to August 13, 2026. KFin Technologies Limited provided the e-voting platform for shareholders.